<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23563" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Insulin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Thota</surname>
            <given-names>Sushmita</given-names>
          </name>
          <aff>NTR University of Health Sciences</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akbar</surname>
            <given-names>Aelia</given-names>
          </name>
          <aff>Loyola University Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Sushmita Thota declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aelia Akbar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23563.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Insulin is a medication used in the treatment and management of diabetes mellitus type-1 and sometimes diabetes mellitus type-2, both of which are significant risk factors for coronary artery disease, stroke, peripheral vascular disease, and a host of other vascular conditions. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of Insulin therapy in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with diabetes and its related conditions and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the mechanism of action of insulin.</p></list-item><list-item><p>Review the adverse effects of insulin therapy.</p></list-item><list-item><p>Summarize the potential toxicity of insulin therapy.</p></list-item><list-item><p>Describe some interprofessional team strategies for improving care coordination and communication to decrease the complications of insulin therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23563&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23563">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23563.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Insulin is a peptide hormone secreted in the body by beta cells of islets of Langerhans of the pancreas and regulates blood glucose levels. Medical treatment with insulin is indicated when there is inadequate production or increased insulin demands in the body.<xref ref-type="bibr" rid="article-23563.r1">[1]</xref></p>
        <p>The FDA-approved indications for treatment with insulin are as follows.</p>
        <p>
<bold>Outpatient Indications for Insulin</bold>
</p>
        <p>Insulin is primarily used for the treatment of diabetes mellitus. According to the American Diabetes Association, in 2018, 34.2 million Americans, or 10.5% of the U.S. population, had diabetes.&#x000a0;Approximately 90&#x000a0;to 95% of patients with diabetes have type 2 or insulin-resistant diabetes, 5 to 10% have type 1 diabetes, and 1&#x000a0;to 2% have maturity-onset of young diabetes (MODY).<xref ref-type="bibr" rid="article-23563.r2">[2]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>In Type 1 or juvenile diabetes mellitus, pancreatic beta cells are destroyed by the body&#x02019;s immune system or trauma or injury to the pancreas, leading to decreased or absent insulin production.<xref ref-type="bibr" rid="article-23563.r3">[3]</xref>&#x000a0;Patients with type-1 diabetes always require insulin.<xref ref-type="bibr" rid="article-23563.r4">[4]</xref><xref ref-type="bibr" rid="article-23563.r5">[5]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Type 2 diabetes mellitus is the most common type of diabetes and usually occurs after the age of 45 years. However, children and teens are also developing it more frequently, mainly due to childhood obesity. In type 2 diabetes, cells are resistant to the action of insulin. The exact cause of this is unknown, but factors such as genetics, obesity, metabolic syndrome, or sedentary lifestyle play a role. As the pancreas secretes more insulin to try to get glucose into the cells, they eventually burn out, and glucose starts building up in the blood. Treatment with insulin is necessary for the later stages of type 2 diabetes.<xref ref-type="bibr" rid="article-23563.r6">[6]</xref><xref ref-type="bibr" rid="article-23563.r7">[7]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Maturity onset diabetes of young (MODY) is an inherited condition in which beta cells of the pancreas cannot secrete insulin due to genetic mutation.<xref ref-type="bibr" rid="article-23563.r8">[8]</xref>&#x000a0;Patients are younger, healthy weight, without antibodies for islet cells of the pancreas, and have first-degree relatives with a similar type of diabetes. Insulin or sulfonylureas are treatment options.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Gestational diabetes mellitus (GDM): Approximately 4% of all pregnancies in the U.S. are complicated by GDM.<xref ref-type="bibr" rid="article-23563.r2">[2]</xref>&#x000a0;Screening for GDM is&#x000a0;performed&#x000a0;during 24 to 28 weeks of pregnancy, and initial treatment is with diet and exercise. Treatment is necessary to prevent complications of preeclampsia, macrosomia, and shoulder dystocia. When diet and exercise fail to control the blood sugar level, insulin is indicated.<xref ref-type="bibr" rid="article-23563.r9">[9]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Inpatient Indications for Insulin</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Management of diabetes mellitus patients in the hospital: Glycemic control in patients with type 1 and type 2 diabetes admitted to general wards for conditions other than diabetes is achievable with subcutaneous or intravenous insulin infusion. This therapeutic approach is to avoid hypoglycemia, hyperglycemia, volume depletion, or electrolyte abnormalities during hospitalization.<xref ref-type="bibr" rid="article-23563.r10">[10]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemia (HHS) are complications of type 1 and type 2 diabetes, respectively, and both represent extremes in hyperglycemia. Insulin is indicated in both DKA and HHS to normalize blood glucose levels.<xref ref-type="bibr" rid="article-23563.r11">[11]</xref><xref ref-type="bibr" rid="article-23563.r12">[12]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Stress-related hyperglycemia: Hyperglycemia in non-diabetic critically ill patients, like ICU, surgical, or trauma patients, is managed by insulin. In stress, hormones like catecholamine, glucagon, growth hormones, cortisol, as well as glycogenolysis and gluconeogenesis, cause hyperglycemia related to poor outcomes in hospitalized patients. Therefore, insulin is used to maintain a blood glucose concentration of 140 to 180 mg/dl in these critically ill patients.<xref ref-type="bibr" rid="article-23563.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of hyperkalemia: IV insulin is used to help manage hyperkalemia in hospitalized end-stage renal disease (ESRD) patients.<xref ref-type="bibr" rid="article-23563.r14">[14]</xref><xref ref-type="bibr" rid="article-23563.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23563.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Insulin acts by directly binding to its receptors on the plasma membranes of the cells. These receptors are present on all the cells, but their density depends on the type of cells, with the maximum density being on the hepatic cells and adipocytes.</p>
        <p>The insulin receptor is a heterotetrameric glycoprotein consisting of two subunits, the alpha and the beta subunits. The extracellular alpha subunits have insulin binding sites. The beta subunits, which are transmembranous, have tyrosine kinase activity.<xref ref-type="bibr" rid="article-23563.r16">[16]</xref>&#x000a0;When insulin binds to the alpha subunits, it activates the tyrosine kinase activity in the beta subunit, which causes the translocation of glucose transporters from the cytoplasm to the cell's surface.<xref ref-type="bibr" rid="article-23563.r17">[17]</xref>&#x000a0;These glucose transporters allow the influx of glucose from the blood into the cell, thus reducing blood glucose levels.<xref ref-type="bibr" rid="article-23563.r18">[18]</xref></p>
        <p>Insulin causes the following effects in the&#x000a0;cells<xref ref-type="bibr" rid="article-23563.r19">[19]</xref>:</p>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic cells: Promotes glycogenesis, inhibits gluconeogenesis</p>
          </list-item>
          <list-item>
            <p>Adipocytes:&#x000a0;Promotes lipogenesis,&#x000a0;inhibits lipolysis</p>
          </list-item>
          <list-item>
            <p>Muscle cells:&#x000a0;Promotes glycogenesis and protein synthesis. Inhibits protein catabolism</p>
          </list-item>
          <list-item>
            <p>Pancreatic beta cells: Inhibits glucagon release</p>
          </list-item>
          <list-item>
            <p>Brain cells: Involved in&#x000a0;appetite regulation</p>
          </list-item>
        </list>
        <p>Depending on the duration of action, insulin is categorized as short-acting, intermediate-acting, and long-acting.</p>
        <p>Rapid-acting insulins (lispro and aspart) start their action in 5&#x000a0;to 15 minutes and peak in 30 minutes. The duration of action is 3&#x000a0;to 5 hours. They are generally used before meals and are always used along with short-acting or long-acting insulins to control sugar levels throughout the day.</p>
        <p>Short-acting (regular insulin) starts the action in 30&#x000a0;to 40 minutes and peaks in 90&#x000a0;to 120 minutes. The duration of action is 6&#x000a0;to 8 hours. Patients take these agents before meals, and food is necessary within 30 minutes after its administration to avoid hypoglycemia.</p>
        <p>Intermediate-acting insulins (NPH) start the action in 1&#x000a0;to 4 hours and peak in 4&#x000a0;to 8 hours. Dosing is usually twice a day and helps maintain blood sugar levels throughout the day.</p>
        <p>Long-acting insulins, such as glargine and detemir, start action in 1&#x000a0;to 2 hours. They provide a plateau effect over 12&#x000a0;to 24 hours. Dosing is usually during the night time after meals. Their long duration of action helps in reducing the frequency of dosing throughout the day.</p>
      </sec>
      <sec id="article-23563.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Insulin administration can be via subcutaneous, intravenous, and intramuscular routes. The route of administration usually depends on the patient's condition and setting.</p>
        <p>The subcutaneous route is the most widespread route of administration and is preferred by most patients due to its ease and convenience in administration. Patients use the subcutaneous route in the form of insulin syringes, pens, and pumps. It is an easy and convenient way for patients to self-administer.</p>
        <p>Intravenous insulin is used in the hospital setting, especially when immediate and close monitoring of blood glucose levels is needed.<xref ref-type="bibr" rid="article-23563.r20">[20]</xref> It is used in patients with diabetic ketoacidosis, hyperosmolar hyperglycemic state, severe hyperkalemia, beta-blocker toxicity, and calcium channel blocker toxicity. All of these cases require emergency treatment, and hence, intravenous insulin is used.</p>
        <p>Intramuscular insulin use is rare and utilizes concentrated regular insulin. In 2014, the FDA approved an inhalable insulin formulation. It passes through the lungs and into the bloodstream and provides a&#x000a0;rapid&#x000a0;onset of action within 12 minutes.&#x000a0;It can be taken by patients with diabetes type 1 and type 2 before meals.&#x000a0;The insulin pump&#x000a0;is a device that works like a natural pancreas.&#x000a0;It replaces the need for long-acting insulin and continuously delivers small amounts of short-acting insulin to the body throughout the day.</p>
      </sec>
      <sec id="article-23563.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Adverse effects of insulin are classified according to those caused by the drug itself and those caused by the specific route of administration. Hypoglycemia is, by far, the most common adverse effect of insulin therapy.<xref ref-type="bibr" rid="article-23563.r21">[21]</xref>&#x000a0;The other adverse effects of insulin therapy include weight gain and rarely electrolyte disturbances like hypokalemia, especially when used along with other drugs causing hypokalemia.</p>
        <p>The subcutaneous route of administration also has adverse effects. Pain at the injection site and lipodystrophy at the injection site are the most common adverse effects of daily subcutaneous injections.<xref ref-type="bibr" rid="article-23563.r22">[22]</xref>&#x000a0;Other adverse effects like peripheral hyperinsulinemia and decreased compliance are also seen in the population using the subcutaneous route for insulin administration.</p>
        <p>Somogyi effect: Some patients who take insulin before bed wake up with high blood sugar levels. This effect occurs when the insulin causes a hypoglycemic condition in the body, which activates hormones such as cortisol and adrenaline, resulting in rebound hyperglycemia; this can be corrected by reducing the dose of bedtime insulin or changing the time of insulin dosing.</p>
        <p>Dawn phenomenon: It is the presence of high blood glucose levels in the body in the early hours of the day due to inadequate insulin in the body. To correct this phenomenon, the dose of bedtime insulin needs to increase to be able to keep the blood glucose levels under control throughout the night and the early hours of the morning.<xref ref-type="bibr" rid="article-23563.r23">[23]</xref></p>
      </sec>
      <sec id="article-23563.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Though there are no absolute contraindications to insulin therapy, the dose of insulin needs to be adjusted and monitored in numerous settings.</p>
        <list list-type="bullet">
          <list-item>
            <p>Insulin dosing requires adjustment in patients with renal impairment and liver failure, as insulin metabolism occurs in the liver, excreted in the urine.</p>
          </list-item>
          <list-item>
            <p>Insulin dose and blood glucose levels should be carefully monitored in patients with a history of hypoglycemic episodes.</p>
          </list-item>
          <list-item>
            <p>Insulin should not be given with other drugs, which also cause hypokalemia, like diuretics.</p>
          </list-item>
          <list-item>
            <p>Vomiting and diarrhea cause a hypokalemic state in the body, and clinicians and patients should exercise care when administering insulin as it also causes hypokalemia.</p>
          </list-item>
          <list-item>
            <p>Insulin is also contraindicated in patients with cresol sensitivity, as insulin preparations contain cresol.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-23563.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Insulin has a low therapeutic index, and blood glucose levels require regular monitoring to avoid adverse effects like hypoglycemia. Patient education should be provided about symptoms of hypoglycemia so that they can take immediate action when necessary. Monitoring for glucose levels is usually performed by fingerstick blood glucose test or glucose sensor device, both of which give instantaneous readings of blood glucose levels. Other tests, such as hemoglobin-A1c, can&#x000a0;estimate glucose&#x000a0;control over the past three months and enable insulin&#x000a0;adjustment accordingly.</p>
      </sec>
      <sec id="article-23563.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Insulin taken in large doses will cause symptoms of hypoglycemia in the patient. Some of these symptoms include headache, dizziness, palpitations, sweating, abdominal pain, and blurred vision. The immediate therapy for such patients is increasing the levels of glucose. In a conscious patient, this can be done by eating a high-energy bar or drinking a glass of glucose water. If the patient is unconscious, he needs to be hospitalized, given dextrose solution intravenously, and continuously monitors glucose levels.</p>
      </sec>
      <sec id="article-23563.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Insulin is a widely used medicine in hospital settings for the management of hyperglycemia. Insulin is regarded as a high alert medication as its misuse is associated with significant risks such as hypoglycemia, and medical errors are common when using it in hospitals.<xref ref-type="bibr" rid="article-23563.r24">[24]</xref><xref ref-type="bibr" rid="article-23563.r25">[25]</xref>&#x000a0;Deal et al. found that the most commonly reported errors were related to missed doses of insulin (25%), timing errors (22.7%), and missed documentation of doses (15.5% of patients).<xref ref-type="bibr" rid="article-23563.r26">[26]</xref> These problems reveal several system errors that merit attention. Rousseau et al. identified various problems causing errors in the hospital use of insulin, such as frequent staff turnover, the involvement of various healthcare providers, none of which are specifically responsible for overall glycemic management, lack of perception of insulin as a &#x0201c;high alert medication,&#x0201d; rapidly evolving diabetes management and lack of education of staff on insulin management.<xref ref-type="bibr" rid="article-23563.r24">[24]</xref>&#x000a0;To minimize these errors following measures should be undertaken,</p>
        <list list-type="bullet">
          <list-item>
            <p>Availability of standardized protocols</p>
          </list-item>
          <list-item>
            <p>Continuing education of providers</p>
          </list-item>
          <list-item>
            <p>Communication between nurses on different shifts</p>
          </list-item>
          <list-item>
            <p>Adequate communication between nurses, physicians, and pharmacists</p>
          </list-item>
          <list-item>
            <p>Training professionals in insulin therapy of inpatients</p>
          </list-item>
        </list>
        <p>Diabetes is a complex disease, and insulin is its most effective treatment. An interprofessional team approach is always essential for the management of diabetes in both outpatient as well as inpatient settings. When prescribing insulin in an outpatient setting, patient education is necessary regarding the disease, use, and side effects of insulin. A variety of healthcare professionals, such as dieticians, endocrinologists, exercise professionals, ophthalmologists, and podiatrists, should work with the patient under the coordination of the primary care providers to manage this disease. [Level 5]</p>
      </sec>
      <sec id="article-23563.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23563&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23563">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23563/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23563">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-23563.s11">
        <title>References</title>
        <ref id="article-23563.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mathieu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gillard</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Benhalima</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Insulin analogues in type 1 diabetes mellitus: getting better all the time.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>13</volume>
            <issue>7</issue>
            <fpage>385</fpage>
            <page-range>385-399</page-range>
            <pub-id pub-id-type="pmid">28429780</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>Diagnosis and classification of diabetes mellitus.</article-title>
            <source>Diabetes Care</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>32 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S62</fpage>
            <page-range>S62-7</page-range>
            <pub-id pub-id-type="pmid">19118289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smith</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Simmons</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cambier</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>B cells in type 1 diabetes mellitus and diabetic kidney disease.</article-title>
            <source>Nat Rev Nephrol</source>
            <year>2017</year>
            <month>Oct</month>
            <day>17</day>
            <volume>13</volume>
            <issue>11</issue>
            <fpage>712</fpage>
            <page-range>712-720</page-range>
            <pub-id pub-id-type="pmid">29038537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Belle</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Coppieters</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>von Herrath</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Type 1 diabetes: etiology, immunology, and therapeutic strategies.</article-title>
            <source>Physiol Rev</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>91</volume>
            <issue>1</issue>
            <fpage>79</fpage>
            <page-range>79-118</page-range>
            <pub-id pub-id-type="pmid">21248163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DiMeglio</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Evans-Molina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oram</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Type 1 diabetes.</article-title>
            <source>Lancet</source>
            <year>2018</year>
            <month>Jun</month>
            <day>16</day>
            <volume>391</volume>
            <issue>10138</issue>
            <fpage>2449</fpage>
            <page-range>2449-2462</page-range>
            <pub-id pub-id-type="pmid">29916386</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donner</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Update on insulin therapy for type 2 diabetes.</article-title>
            <source>J Clin Endocrinol Metab</source>
            <year>2012</year>
            <month>May</month>
            <volume>97</volume>
            <issue>5</issue>
            <fpage>1405</fpage>
            <page-range>1405-13</page-range>
            <pub-id pub-id-type="pmid">22442275</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howard-Thompson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Type 2 Diabetes Mellitus: Outpatient Insulin Management.</article-title>
            <source>Am Fam Physician</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>97</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-37</page-range>
            <pub-id pub-id-type="pmid">29365240</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>An&#x00131;k</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>&#x000c7;atl&#x00131;</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Abac&#x00131;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>B&#x000f6;ber</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Maturity-onset diabetes of the young (MODY): an update.</article-title>
            <source>J Pediatr Endocrinol Metab</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>28</volume>
            <issue>3-4</issue>
            <fpage>251</fpage>
            <page-range>251-63</page-range>
            <pub-id pub-id-type="pmid">25581748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patti</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Giglio</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Pafili</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Papanas</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Pharmacotherapy for gestational diabetes.</article-title>
            <source>Expert Opin Pharmacother</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>13</issue>
            <fpage>1407</fpage>
            <page-range>1407-1414</page-range>
            <pub-id pub-id-type="pmid">30136869</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <collab>American Diabetes Association</collab>
            <article-title>15. Diabetes Care in the Hospital: <italic>Standards of Medical Care in Diabetes-2020</italic>.</article-title>
            <source>Diabetes Care</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>43</volume>
            <issue>Suppl 1</issue>
            <fpage>S193</fpage>
            <page-range>S193-S202</page-range>
            <pub-id pub-id-type="pmid">31862758</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Umpierrez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Korytkowski</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia.</article-title>
            <source>Nat Rev Endocrinol</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>222</fpage>
            <page-range>222-32</page-range>
            <pub-id pub-id-type="pmid">26893262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomovsky</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Fluid and Electrolyte Therapy in Diabetic Ketoacidosis.</article-title>
            <source>Vet Clin North Am Small Anim Pract</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>491</fpage>
            <page-range>491-503</page-range>
            <pub-id pub-id-type="pmid">28017407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanhorebeek</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Gunst</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Van den Berghe</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Critical Care Management of Stress-Induced Hyperglycemia.</article-title>
            <source>Curr Diab Rep</source>
            <year>2018</year>
            <month>Feb</month>
            <day>26</day>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>17</fpage>
            <pub-id pub-id-type="pmid">29479638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ahmed</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Weisberg</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Hyperkalemia in dialysis patients.</article-title>
            <source>Semin Dial</source>
            <year>2001</year>
            <season>Sep-Oct</season>
            <volume>14</volume>
            <issue>5</issue>
            <fpage>348</fpage>
            <page-range>348-56</page-range>
            <pub-id pub-id-type="pmid">11679104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Long</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Warix</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Koyfman</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Controversies in Management of Hyperkalemia.</article-title>
            <source>J Emerg Med</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>55</volume>
            <issue>2</issue>
            <fpage>192</fpage>
            <page-range>192-205</page-range>
            <pub-id pub-id-type="pmid">29731287</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kahn</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>The molecular mechanism of insulin action.</article-title>
            <source>Annu Rev Med</source>
            <year>1985</year>
            <volume>36</volume>
            <fpage>429</fpage>
            <page-range>429-51</page-range>
            <pub-id pub-id-type="pmid">2986528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Posner</surname>
                <given-names>BI</given-names>
              </name>
            </person-group>
            <article-title>Insulin Signalling: The Inside Story.</article-title>
            <source>Can J Diabetes</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>41</volume>
            <issue>1</issue>
            <fpage>108</fpage>
            <page-range>108-113</page-range>
            <pub-id pub-id-type="pmid">27614806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jaldin-Fincati</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Pavarotti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Frendo-Cumbo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bilan</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Klip</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Update on GLUT4 Vesicle Traffic: A Cornerstone of Insulin Action.</article-title>
            <source>Trends Endocrinol Metab</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>597</fpage>
            <page-range>597-611</page-range>
            <pub-id pub-id-type="pmid">28602209</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wilcox</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Insulin and insulin resistance.</article-title>
            <source>Clin Biochem Rev</source>
            <year>2005</year>
            <month>May</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>19</fpage>
            <page-range>19-39</page-range>
            <pub-id pub-id-type="pmid">16278749</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>P&#x000e9;rez</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramos</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carreras</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Insulin Therapy in Hospitalized Patients.</article-title>
            <source>Am J Ther</source>
            <year>2020</year>
            <season>Jan/Feb</season>
            <volume>27</volume>
            <issue>1</issue>
            <fpage>e71</fpage>
            <page-range>e71-e78</page-range>
            <pub-id pub-id-type="pmid">31833876</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Unger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Parkin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Hypoglycemia in insulin-treated diabetes: a case for increased vigilance.</article-title>
            <source>Postgrad Med</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>123</volume>
            <issue>4</issue>
            <fpage>81</fpage>
            <page-range>81-91</page-range>
            <pub-id pub-id-type="pmid">21680992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radermecker</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Pi&#x000e9;rard</surname>
                <given-names>GE</given-names>
              </name>
              <name>
                <surname>Scheen</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Lipodystrophy reactions to insulin: effects of continuous insulin infusion and new insulin analogs.</article-title>
            <source>Am J Clin Dermatol</source>
            <year>2007</year>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-8</page-range>
            <pub-id pub-id-type="pmid">17298103</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rybicka</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Krysiak</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okopie&#x00144;</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>The dawn phenomenon and the Somogyi effect - two phenomena of morning hyperglycaemia.</article-title>
            <source>Endokrynol Pol</source>
            <year>2011</year>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>276</fpage>
            <page-range>276-84</page-range>
            <pub-id pub-id-type="pmid">21717414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rousseau</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Beauchesne</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Naud</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Leblond</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cossette</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lanthier</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Grondin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Bernier</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>An interprofessional qualitative study of barriers and potential solutions for the safe use of insulin in the hospital setting.</article-title>
            <source>Can J Diabetes</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>85</fpage>
            <page-range>85-9</page-range>
            <pub-id pub-id-type="pmid">24690502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cohen</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Pharmacists' role in ensuring safe and effective hospital use of insulin.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>67</volume>
            <issue>16 Suppl 8</issue>
            <fpage>S17</fpage>
            <page-range>S17-21</page-range>
            <pub-id pub-id-type="pmid">20689148</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23563.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deal</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wise</surname>
                <given-names>LL</given-names>
              </name>
              <name>
                <surname>Honick</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Tobin</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Inpatient insulin orders: are patients getting what is prescribed?</article-title>
            <source>J Hosp Med</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>6</volume>
            <issue>9</issue>
            <fpage>526</fpage>
            <page-range>526-9</page-range>
            <pub-id pub-id-type="pmid">22042479</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
